Page 1

2009 Research Report

The researchers at Children’s Hospitals and Clinics of Minnesota are recognized internationally for their excellent care and outcomes. Our professional staff has been invited to participate in networks, consult as experts, and coordinate cooperative agreements in national initiatives and clinical research trial networks. Partnerships with entities such as the Therapeutic Development Network of the Cystic Fibrosis Foundation, Children’s Oncology Group, and the Pediatric Heart Network enable clinical research centers worldwide to consolidate research efforts and provide patients with leading edge treatments.

Therapeutic Development Network (TDN): According to recent TDN center data, Children’s Cystic Fibrosis Program is ranked in the top third of all centers participating in similar research for timely enrollment of patients from enrollment approval date to study inception.

The Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI): The Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) is a North American collaboration of clinical investigators in pediatric intensive care units. Researchers collaborate to identify supportive, preventive, and therapeutic strategies for acute lung injury, sepsis, multi-organ failure, and other acute, life-threatening pulmonary or systemic inflammatory syndromes that affect infants and children.

Children’s Oncology Group (COG): Children’s is among the top 10 hospitals, medical centers, and research institutes in COG for numbers of children with newly diagnosed cancer treated each year. Through successful international partnerships and collaborations related to the treatment and prevention of childhood cancer, Children’s is able to provide clinical trials for childhood cancer treatment and help develop the most effective treatment protocols. Importantly, Children’s is ranked eighth out of the 235 hospitals participating in COG.

Hemophilia Treatment Center (HTC): Children’s is a designated Hemophilia Treatment Center, and through the Centers for Disease Control and Prevention (CDC), is dedicated to the advancement of treatments and cures for bleeding and clotting disorders and prevention of complications through education, advocacy, and research.

Pediatric Heart Network (PHN): Children’s Cardiovascular and Critical Care Research Center participates in the PHN, a group of hospitals conducting research studies in children with congenital or acquired heart disease.

Every day, we find inspiration from the children and families we serve and from the researchers at Children’s who are committed to finding answers. Each researcher fulfills the promise of our vision to seek knowledge that will benefit children for generations to come. The excitement of our scientific inquiry resonates in the pages of this report. The studies featured are only a small representation of the research being conducted at Children’s. Our diabetes/endocrinology group collaborates in state-of-the-art research to enhance daily living for children with diabetes and endocrine disorders. The cystic fibrosis team is involved in clinical trials to conquer debilitating symptoms and continues to demonstrate excellent outcomes. Cardiovascular and critical care research illustrates an elegant collaboration between two of our cornerstone service lines committed to improving health and mortality for children and their families. Hematology/oncology gained national recognition for identifying the DICER1 gene and continues leadingedge investigator-initiated research to help children with cancer live developmentally normal lives. The Telehealth Institute for Child Maltreatment reaches across the nation to ensure that any child who is a victim of sexual abuse receives an appropriate and timely diagnosis. The Infant Diagnostic and Research Center is committed to changing outcomes for premature and critically ill infants.

Table of Contents

Research at Children’s often yields dramatic, positive results. We are proud to be associated with such talented researchers who continuously stop to ask: “What can I do to make a difference?” Their ongoing mission is to help our children and families thrive and reach their full potential.

Phillip M. Kibort, MD, MBA Vice President of Medical Affairs and Chief Medical Officer

Laurie Blumberg-Romero, MA Director, Research and Sponsored Programs



Cystic Fibrosis


Cardiovascular and Critical Care (CVCC)




Telehealth Institute for Child Maltreatment (THICM) 12 The Infant Diagnostic and Research Center (IDRC)


Research Financials


Selected Grant Awards


Peer-Reviewed Publications


Research Staff and Vision


Novel therapies and technology enhance quality of life Exploring solutions for diabetes management


Children’s diabetes care team is aggressively seeking best practices to help children and their families consistently monitor blood sugar, activity, food, and regular injections. Diabetes, one of the most common chronic childhood diseases, impacts the lives of approximately 1.9 out of every 1,000 children in the United States. Diabetes occurs when the body does not produce an adequate amount of insulin needed to convert sugar and starches into energy. Management is complex, requiring daily monitoring of blood sugars and balancing food, exercise, insulin, and other medication. “Our providers are passionate about taking care of patients. As a group, we will do whatever we can to improve quality of life for patients and families. We focus on clinical research as a means to achieve this goal,” stated Jennifer Kyllo, MD.

Examining new diabetes technology through clinical studies Children’s McNeely Diabetes Center and Endocrine Clinic is currently involved in nine open clinical studies. One area of research interest is exploring whether adult-focused technologies and medications can be used by children to improve health outcomes and quality of life. As part of a multi-center trial, Children’s is partnering with Medtronic to investigate the use of newer diabetes technology for children. The focus of this research is to ascertain if new technology will allow children to shift their daily routines so they can eat what they want, when they want, worry less about low blood sugars, and avoid the inconvenience of monitoring blood sugars throughout the day.

Controlling hypothalamic obesity with drug therapy Craniopharyngioma, a slow-growing, nonmalignant brain tumor, accounts for 6 to 10 percent of all brain tumors in children, and 2

occurs most commonly in children between the ages of 5 and 14. It is the third most common intracranial brain tumor in children. Children undergo surgical removal with radiation for recurrence of this tumor. One adverse outcome often observed is hypothalamic obesity that results from damage to the hypothalamus. M. Jennifer Abuzzahab, MD, and her research team at Children’s are evaluating the effect of exenatide on weight gain and obesity in this pediatric population. Administered through subcutaneous injections, exenatide is a synthetic hormone agonist for gut-derived hormone glucagon-like peptide-1 (GLP-1). One of the main mechanisms of exenatide is to enhance glucose disposal in the postprandial setting and improve glucose tolerance. In addition, exenatide can induce weight loss by decreasing appetite and slowing gastric motility. Also being evaluated is the effect of exenatide on calorie intake, satiety, and quality of life. The hypothesis is that exenatide given to children with hypothalamic obesity will reduce their weight significantly from baseline to endpoint. It is also hypothesized that calorie intake will decrease, while satiety and quality of life ratings increase.

Fostering inquiry Children’s is actively involved in the following additional research: TrialNet, a National Institutes of Health (NIH) sponsored multi-center national network, looks at natural history and treatment of children with Type I diabetes. In partnership with Naval Medical Center, researchers are looking for the genetic marker that causes Type I diabetes.

Elizabeth Potratz, BSN, RN, clinical diabetes educator, teaches a patient with diabetes how to use a glucose monitor.


Clinical trials bridge the gap between debilitating symptoms and excellent outcomes Cystic Fibrosis

Early detection and treatment alleviate symptoms Our cystic fibrosis (CF) multidisciplinary care team seeks to improve the quality of life and extend the life expectancy for children with cystic fibrosis by achieving optimal nutritional status, preventing lung infections, and maintaining multi-organ function. Cystic fibrosis is a life-limiting disease that impacts 70,000 children and adults worldwide, including 30,000 in the United States. Approximately 1,000 new cases of CF are diagnosed each year; and more than 70 percent of these cases are identified by age two. Adding CF testing to newborn screening, which has been taking place in the state of Minnesota since 2006, allows for early detection and proactive treatment. Today, the median life expectancy for children with CF is more than 37 years. This number increases every year due to advances in clinical care and enhanced research.

Innovative collaborations lead to promising CF therapies In 2009, the CF program at Children’s was awarded Therapeutic Development Network (TDN) Center status through the CF Foundation, which is providing Children’s with the potential to pursue new networking and research opportunities. John McNamara, MD, and his team are currently evaluating the safety and efficacy of two CF treatments. The Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) is exploring the use of 7 percent hypertonic saline in patients with CF, ages four months to five years. Children’s is also participating with Inspire Pharmaceuticals, Inc. on a multi-center, randomized trial to evaluate the use of denufosol (an investigational drug) vs. placebo delivered via inhalation in 450 patients with CF (www.; Study ID:NCT00625612). Denufosol is a P2Y2 receptor agonist designed to enhance the lungs’ innate mucosal hydration and mucociliary clearance mechanisms, which in CF patients are impaired due to a genetic defect. Activation of the P2Y2 receptor may bypass this defect to hydrate airways and 4

Cystic fibrosis patients are susceptible to chronic respiratory infections due to thick mucus that blocks their airways. Research at Children’s focuses on therapies that keep the lungs clear, thereby reducing infections.

stimulate mucociliary clearance. Thus, denufosol may have the potential to help keep the lungs of CF patients clear of thickened mucus, reduce infections, and limit the damage that occurs as a consequence of the prolonged retention of thick, infected secretions.

Yoga study targets depression and anxiety Based on an investigator-initiated study, researchers at Children’s found that pediatric patients with CF often have a negative perception of their bodies, experience significant sleep problems, have limb and joint pain, and suffer from severe depression and anxiety. Based on this data, researchers are now exploring the potential benefits of yoga on children with CF. The strength of this data as well as information gathered about the families’ desire for complementary therapy, led to the development of the yoga study titled: Evaluating the effects of yoga on children with cystic fibrosis: pain, sleep, anxiety, and depression.

Mahrya Johnson, senior clinical research coordinator, interacts with a patient during a clinical visit.

“Our continued excellent outcomes and increasing involvement in clinical research is a tribute to the passion of the multidisciplinary CF team. For over 20 years, the team has focused on continuous quality improvement in the care of children with CF.� John McNamara, MD

Collaboration between two service lines improves health and mortality Clinical needs drive state-of-the-art research

Cardiovascular and Critical Care (CVCC)

The Cardiovascular and Critical Care (CVCC) Research Center was created in 2009 to demonstrate the proven multidisciplinary collaboration between the cardiovascular and critical care departments. Research is prioritized based on clinical improvements in care. These range from drug studies to longitudinal outcome surveillance projects that highlight groundbreaking methodologies. Improved health and mortality for children and families is the top priority. Our collaborative infrastructure supports a full scope of research projects through the thoughtful use of state-of-the-art technologies, treatments, and pharmaceuticals.

Improving outcomes for atrioventricular septal defects With the goal of providing the best possible outcomes for patients with unbalanced atrioventricular septal defect (AVSD), David Overman, MD, initiated the collaboration of five pediatric institutions in a retrospective analysis of the treatment of this defect. AVSD is a rare heart abnormality characterized by the failure of the heart chambers to separate, and accounts for 5 percent of all congenital heart defects. Overman and his study team are reviewing and analyzing medical records including echocardiograms performed over the past 10 years from the participating institutions. The objective is to establish clear criteria for determining optimal treatment strategies in unbalanced AVSD.

Research targets life-threatening complications in children with marfan syndrome Marfan syndrome is a genetic disorder of connective tissue with a prevalence of approximately 1 per 5,000 people. Today, standard of care therapy for these individuals is beta-blocker therapy, such as atenolol, which reduces the rate of aortic growth. Through significant research, the life expectancy and quality of life of individuals 6

with marfan syndrome has increased, but patients continue to suffer cardiovascular morbidity and mortality. Mary Ella Pierpont, MD, geneticist/cardiologist, and Charlie Baker, MD, cardiologist, are joint investigators on a multi-institutional, randomized clinical trial with 30 sites throughout the U.S., Canada, and Europe. This study is sponsored by the National Heart, Lung, and Blood Institute and conducted through the Pediatric Heart Network. This study is exploring the effects of atenolol and losartan on aortic root growth, a leading cause of death in individuals with marfan syndrome. Recent studies have shown that angiotensin II receptor blockers, like losartan, have normalized aortic root growth, ultimately preventing premature death. The primary aim of the study is to compare the effects of atenolol therapy to those of losartan on aortic root growth and other short-term cardiovascular outcomes.

Innovative research inspires excellence in empyema pneumonia care From diagnosis to treatment, Children’s is always looking for ways to provide stateof-the-art care for our children. Improving the Care of Children with Pneumonia is an institution-wide study to improve the care of children with pneumonia and empyema (chest cavity infection) by creating a clinical benchmark that minimizes practice variation and limits delay in decision-making. Stephen Kurachek, MD, in collaboration with radiology, infectious disease, the emergency department, and hospitalists is collecting data in order to develop a standardized treatment and intervention plan for children who are hospitalized with pneumonia. These findings promise to create a consistent approach for the care of children with pneumonia hospital-wide. The focus is on designating immunologic and situational risk associated with the consistent use of antibiotics, including the selection and length of use, as well as standardizing both imaging and laboratory studies for the population as a whole.

David Gremmels, MD, helps a patient listen to the sound of his own heart.


Investigator-initiated research awakens balance and strength Maintaining national presence in pediatric oncology research


The hematology/oncology research team at Children’s is actively involved with Children’s Oncology Group (COG), the world’s most prominent pediatric cancer research organization. Children’s ranks in the top 10 of COG institutions for patient enrollment. With 132 clinical research-driven specialty studies, 95 of which are clinical trials, Children’s is at the forefront of pediatric oncology research with ongoing studies that are well-integrated into national research. Children’s also participates in other clinical trial groups, such as Therapeutic Advances in Childhood Leukemia (TACL). Research at Children’s promotes the current and future physical and emotional development of children undergoing cancer treatment. Researchers believe that children with cancer can live a developmentally normal life in relation to physical activity, social interaction, and school. Children’s is pioneering new treatments and cures to minimize side effects and enhance patients’ quality of life.

Hemophilia Treatment Center provides on-site comprehensive services Children’s federally funded Hemophilia Treatment Center (HTC) within the hematology/oncology clinic participates in the national Universal Data Collection Registry (UDC) for patients with bleeding disorders. The purpose of the registry, coordinated through the Centers for Disease Control and Prevention (CDC), is to gain a better understanding of ways to reduce or prevent complications of bleeding disorders and to create a uniform set of routinely collected clinical data. “Children’s HTC belongs to a nationwide network of federally funded hemophilia and thrombosis centers and is the only such program in the region focused solely on pediatrics,” said Margaret Heisel Kurth, MD. “This designation ensures that children receive comprehensive care, including diagnostic evaluations, treatment, and care coordination.” 8

Investigating with passion Laura Gilchrist, PT, PhD, has dedicated her career to finding new ways to improve physical function in children undergoing cancer treatment. With Lynn Tanner, PT, she is exploring ways to measure chemotherapy-induced damage to peripheral nerves in the hands and feet. While this issue is well described in adults, Gilchrist is developing a measurement tool specifically for use in children to determine which changes in nerve function are permanent, with the goal of preventing such damage. This tool will not only help Children’s patients, but will be utilized by health care providers and researchers across the country to more precisely evaluate this treatment-related side effect. This is the first step in her quest to create a new model that integrates physical status into the care of cancer patients. In a second study led by Gilchrist, children at the end of cancer treatment are being evaluated for balance, endurance, strength, posture, and walking mechanics. She is using a state-of-theart computerized walkway system to collect information on changes in walking mechanics. Potential deficits such as decreased step length, foot drop, and changes in gait patterns are measured using this novel device. Research outcomes will potentially help children maintain motor development during treatment and prevent chronic late effects, such as obesity and decreased bone mineral density. Megan V. Thygeson, a certified yoga instructor; Casey Hooke, RN, PhD, CPON; and her team completed the Peaceful Play study to evaluate the benefits of yoga for children, teens, and their parents hospitalized for treatment of cancer or blood disorders. Study results show that after a single 45-minute inpatient yoga class, parents and teens experience a significant decrease in anxiety and an improved sense of well being. The group is planning future studies to determine the benefits of yoga over a longer period of time.

With guidance from Laura Gilchrist, PT, PhD, a patient regains balance and stability.

“Now that the vast majority of children survive cancer due to advances in cancer treatment, we must understand the physical deficits that treatment brings and intervene in order to maintain normal motor development and improve their quality of life.� Laura Gilchrist, PT, PhD

Genetic link to pleuropulmonary blastoma (PPB) found Hematology/Oncology

Gene mutation discovery leads to early detection of PPB The search for the cause of an inherited form of a rare, aggressive childhood lung cancer has uncovered important information about how the cancer develops, and potentially sheds light on the development of other cancers. Children’s physicians Yoav Messinger, MD, and Jack Priest, MD, MBA, partnered with colleagues at Children’s of St. Louis and Children’s National in the discovery that some children with the rare cancer pleuropulmonary blastoma (PPB) are born with a deleterious mutation in the DICER1 gene. “For years, our large collection of PPB cases and families has revealed the strong genetic component of this disease,” said Priest, who is the research director of the International PPB Registry at Children’s. “We are thrilled to have uncovered an important mutation and we have begun to understand the cellular mix-up which results in malignancy.” The DICER1 gene is a master controller gene that helps regulate expressions of other genes. This research adds the final link to the chain connecting the DICER1 gene to cancer development—something that had been suspected, but until now had not definitively been demonstrated. Only 50 to 60 cases of PPB are diagnosed each year around the world. Most children with PPB are under five years of age. The cancer progresses from air-filled lung cysts in the early stage to solid lung tumors in later stages. If detected in the earliest stage, 90 percent of patients appear to be cured when treated with surgery and sometimes chemotherapy. Survival drops to about 40 percent if the cancer is diagnosed in the latest stage. The researchers found that all the children studied with PPB carried damaging mutations in one of their DICER1 genes, giving them 10

one functional and one non-functional DICER1 gene in all their body’s cells. The researchers indicated that PPB lung tumors probably originate when one or more cells in the lung acquire a harmful mutation in their functional copy of the DICER1 gene. “Having identified this gene will allow us to focus on early detection in children who are most susceptible,” stated Messinger. “The findings could help us diagnose and treat children in the earliest stage of this disease, when PPB is by far the most curable.”

PPB Registry facilitates family connections In the summer of 2008, 31 families with PPB survivors gathered in Minneapolis from across the United States and as far away as Australia, Ireland, and Canada to share a sense of hope. Virtually connected through the PPB Registry Web site (, they were offered the chance to meet face to face. The PPB Registry is the only international resource to offer diagnosis, treatment, and surveillance information for providers and families.

Children’s has been the home to the International PPB Registry since its inception in 1988 and follows more than 270 confirmed PPB cases from 21 countries.

Yoav Messinger, MD, examines a patient in the new Children’s Specialty Center.


Web-based technology leads to accurate diagnosis of abuse Increasing access for medically underserved areas

Telehealth Institute for Child Maltreatment (THICM)

Child abuse is a persistent and tragic problem in the United States. In most cases, rural and medically underserved areas have no access to medical expertise. Rich Kaplan, MD, partnered with VisualShare to envision and develop a telehealth solution using Web-based imaging technology that facilitates peer review of suspected abuse cases by connecting medical providers with experts in tertiary care centers.

This image demonstrates the flow of case collection, expert review, and subsequent research for suspected abuse cases. Labs and Research

The overarching goal of the Telehealth Institute for Child Maltreatment (THICM) is to reach across the nation to provide mentorship to community medical providers, regardless of geographic location. Under the direction of Kaplan, THICM is housed at Children’s. Through medical technology and peer review mentoring, THICM ensures timely and accurate diagnosis for all children who are possible victims of sexual abuse. Cutting edge TeleCAM technology facilitates high resolution, quality review of cases uploaded into a HIPAA compliant server using both store and forward, and real-time conferencing modalities. As each case is submitted by a medical provider, a THICM expert reviewer provides prompt feedback regarding the accuracy of the exam interpretation. The submissions are anonymous and reviewers are blinded to the identity of the submitting provider. This model was developed by an unprecedented national coalition of medical providers, governmental, and corporate partners. Kaplan and colleague Lori Frasier, MD, medical director of the Safe and Healthy Families at Children’s Primary Medical Center, Utah, began providing this innovative peer review technology to medical professionals in remote centers in Utah, Alaska, South Dakota, and Nebraska. The services are now offered nationwide.





Robert Shapiro, MD, medical director for Safe and Healthy Children at Cincinnati Children’s Hospital Medical Center, and Frasier, in collaboration with Children’s, are researching the collated pre and post review data to determine and analyze case demographics, trends, and the effectiveness of THICM in the accurate diagnosis of child abuse. The work promises to provide invaluable feedback regarding diagnostic skills and to overcome geographic and cultural disparities suffered by child abuse victims who lack consistent, high quality medical care. “THICM is an ambitious quality improvement project. If proven effective, this mentorship process combined with the TeleCAM software can be applied to many medical specialties beyond child abuse,” stated Shapiro.

“The use of this innovative technology in conjunction with peer review mentoring, ensures accessibility to an accurate diagnosis for all medical professionals, regardless of geographic area, who are treating children suspected of abuse.� Rich Kaplan, MD

Jane Braun, MA, Emeritus LSW, and Anne McDonald, LSW, review a child maltreatment case using Web-based technology.

Clinical investigation changes outcomes for premature and critically ill infants The Infant Diagnostic and Research Center (IDRC)

Cultivating research to sustain tiny heartbeats Children’s has been providing compassionate care to premature and critically ill newborns for more than 30 years. Their future is at the heart of the mission of the Infant Diagnostic and Research Center, part of Children’s Neonatal Cornerstone Program. Today, our neonatal intensive care units provide life-sustaining treatments to more than 2,000 babies each year with critical or debilitating conditions such as respiratory distress syndrome, extreme prematurity, retinopathy of prematurity, birth asphyxia, meconium aspiration, and pulmonary hypertension, as well as infants who undergo heart, lung, and gastrointestinal surgery. Researchers within the Infant Diagnostic and Research Center, founded in 1979, have produced more than 100 publications and actively participate in local and national research projects. The Center’s commitment to investigation and clinical implementation of new technology enhances outcomes for premature and critically ill infants.

or ibuprofen. However, recent evidence from animal and human studies indicates that the practice of withholding infant feedings for several days may lead to subsequent feeding difficulties. The research team posited that feeding infants while receiving indomethacin or ibuprofen therapy will lessen changes in intestinal permeability that occurs with these drugs and will improve the infants’ blood flow response to tube-fed nutrition. They hypothesized that this will decrease the incidence of feeding intolerance and shorten the time before infants are able to tolerate full liquid tube feedings. “If the hypothesis of this trial is confirmed, current clinical practice will be altered and new guidelines for infant nutrition will be established for preterm infants receiving indomethacin or ibuprofen treatment for PDA,” said Robert Couser, MD.

Redesigning feeding protocol for preterm infants Approximately 25,000 premature infants per year receive indomethacin or ibuprofen during the newborn period to treat the symptoms of a patent ductus arteriosus (PDA). Ductus arteriosis is open during the fetal period so blood can bypass the lungs when oxygen is received from the placenta. It normally closes at birth, but may remain open in premature infants. If left uncorrected, this can result in pulmonary hypertension and possibly congestive heart failure and cardiac arrhythmias. In a multi-center, randomized controlled trial, Children’s researchers explored the efficacy of enteral feedings during the time an infant is being treated with one of these medications. Currently, 85 percent of U.S. neonatologists withhold feedings when using indomethacin 14

“The IDRC is a homegrown group that has been a real success story. We have helped advance respiratory care of newborn infants, helped train new physicians in newborn medicine, and are recognized as innovative thinkers. Today’s research is tomorrow’s treatment.” Mark Mammel, MD

Robert Couser, MD, cares for a premature infant in the NICU.


Research Financials 2009 Awards by Funding Source Total

Federal 32.2% State/Local Government 19.6% Industry 17.2% Academic Sub-awards 4.8% Foundation 26.2%

Funding Amounts by Sponsor Type Totals



Federal $ 1,000,314 $ 706,855 $ State/Local Government 1,723,811 1,717,681 Industry 564,795 1,038,910 Academic Sub-awards 328,739 153,904 Foundation 1,421,513 1,908,673 Total


$ 5,039,172

$ 5,526,023

2008 1,993,734 $ 1,195,663 1,163,637 108,480 1,994,619

$ 6,456,133

2009 2,474,653 1,509,944 1,321,646 371,921 2,017,800

$ 7,695,964

Selected Grant Awards Jane Braun, MA, Emeritus LSW,

Mary Ella Pierpont, MD

Midwest Regional Children’s Advocacy Centers (MRCAC) Department of Justice (DOJ) $1,250,000

Trial of Beta Blocker Therapy (Atenolol) Vs. Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals with Marfan Syndrome National Institutes of Health – National Heart Lung and Blood Institute (NHLBI) Pediatric Heart Network $423,000

Laurel Edinburgh, RN, CNP Community Intervention Program (CIP) Title V Maternal Child Health Services for Improving Adolescent Health St. Paul Ramsey County – Department of Public Health $65,200

Susan Forvé, MBA, M.Ed Health Care and Other Facilities – Simulation Equipment Health Resources and Services Administration (HRSA) $298,620

Richard Kaplan, MD Teleconsultation and Quality Review in Child Maltreatment National Institutes of Health – Small Business Innovation Research (SBIR) VisualShare $42,587

James McCord, MD Telehealth Nursing Intervention for Children with Complex Health Care Needs National Institutes of Health – National Institute of Nursing Research (NINR) University of Minnesota $154,569

John McNamara, MD

Stacy Remke, MSW, LICSW Children’s Institute for Pain and Palliative Care: National Outreach Project Health Resources and Services Administration (HRSA) $238,313

Mark Schumann, MT, ASCP Health Information Technology Grant Health Resources and Services Administration (HRSA) $235,000

Emily Scribner-O’Pray, BA Eliminating Health Disparities Grant (EHDI) Minnesota Department of Health (MDH) $222,854

Patsy Stinchfield, RN, MS, CPNP Assessing the Public Health Impact of the U.S. Rotavirus Vaccination Program through the Emerging Infections Program Network Centers for Disease Control (CDC) Minnesota Department of Health (MDH) $87,372

Therapeutics Development Center Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) $64,800


Peer-Reviewed Publications Anderson F. S., Kunin-Batson A. S., Perkins J. L., Scott Baker K. White versus gray matter function as seen on neuropsychological testing following bone marrow transplant for acute leukemia in childhood. Neuropsychiatr Dis Treat. 2008;4(1):283-288. Anderson R., Malone G. What about the children? Special administration concerns. Nurs Adm Q. 2009;33(1):3-4. Arms J. L., Mackenberg-Mohn M. D., Bowen M. V., Chamberlain M. C., Skrypek T. M., Madhok M., Jimenez-Vega J. M., Bonadio W. A. Safety and efficacy of a protocol using bougienage or endoscopy for the management of coins acutely lodged in the esophagus: a large case series. Ann Emerg Med. 2008;51(4):367-372. Arms J. L., Ortega H., Reid S. Chronological and clinical characteristics of apnea associated with respiratory syncytial virus infection: a retrospective case series. Clin Pediatr (Phila). 2008;47(9):953-958. Arndt C. A., Hawkins D. S., Meyer W. H., Sencer S. F., Neglia J. P., Anderson J. R. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2008;50(1):33-36. Aucott S. W., Watterberg K. L., Shaffer M. L., Donohue P. K., Couser R., Mammel M.C. Do cortisol concentrations predict shortterm outcomes in extremely low birth weight infants? Pediatrics. 2008;122(4):775-781. Berkowitz S. Transitioning adolescents to adult care: putting theory into practice. Minn Med. 2009;92(3):42-44. Biros M. H., Hick K., Cen Y. Y., Mann J., Gaetz A., Hansen R., Schiming R. Occult depressive symptoms in adolescent emergency department patients. Arch Pediatr Adolesc Med. 2008;162(8):769773. Bluhm E. C., Ronckers C., Hayashi R. J., Neglia J. P., Mertens A. C., Stovall M., Meadows A. T., Mitby P. A., Whitton J. A., Hammond S., Barker J. D., Donaldson S. S., Robison L. L., Inskip P. D. Causespecific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2008;111(8):4014-4021. Bostrom B. C. Effective Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole once a day twice a week. Pediatr Blood Cancer. 2009;53(2):239. Breningstall G. N., Patterson R. J. Acquired obstructive hydrocephalus in globoid-cell leukodystrophy. Pediatr Neurol. 2008;39(4):279-280. Buchanan N., Leisenring W., Mitby P. A., Meadows A. T., Robison L. L., Hudson M. M., Mertens A. C. Behaviors associated with ultraviolet radiation exposure in a cohort of adult survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study. Cancer. 2009;115(18 Suppl):4374-4384.


Carlson-Green B. Brain tumor survivors speak out. J Pediatr Oncol Nurs. 2009;26(5):266-279. Casares S., Lin M., Zhang N., Teijaro J. R., Stoica C., McEvoy R., Farber D. L., Bona C., Brumeanu T. D. A peptide-major histocompatibility complex II chimera favors survival of pancreatic beta-islets grafted in type 1 diabetic mice. Transplantation. 2008;85(12):1717-1725. Chi S. N., Zimmerman M. A., Yao X., Cohen K. J., Burger P., Biegel J. A., Rorke-Adams L. B., Fisher M. J., Janss A., Mazewski C., Goldman S., Manley P. E., Bowers D. C., Bendel A., Rubin J., Turner C. D., Marcus K. J., Goumnerova L., Ullrich N. J., Kieran M. W. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009;27(3):385-389. Chang Milbauer L., Wei P., Enenstein J., Jiang A., Hillery C. A., Scott J. P., Nelson S. C., Bodempudi V., Topper J. N., Yang R. B., Hirsch B., Pan W., Hebbel R. P. Genetic endothelial systems biology of sickle stroke risk. Blood. 2008;111(7):3872-3879. Conry J. A., Ng Y. T., Paolicchi J. M., Kernitsky L., Mitchell W. G., Ritter F. J., Collins S. D., Tracy K., Kormany W. N., Abdulnabi R., Riley B., Stolle J. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia. 2009;50(5):1158-1166. Culbert T. P., Banez G. A. Wetting the bed: integrative approaches to nocturnal enuresis. Explore (NY). 2008;4(3):215-220. Edinburgh L., Saewyc E., Levitt C. Caring for young adolescent sexual abuse victims in a hospital-based children’s advocacy center. Child Abuse Negl. 2008;32(12):1119-1126. Edinburgh L., Swenson J. Building intervention responses for sexually exploited, runaway youth. Nurs Adm Q. 2009;33(1):62-64. Edinburgh L. D., Saewyc E. M. A novel, intensive home-visiting intervention for runaway, sexually exploited girls. J Spec Pediatr Nurs. 2009;14(1):41-48. Fahlman A., Hooker S. K., Olszowka A., Bostrom B. L., Jones D. R. Estimating the effect of lung collapse and pulmonary shunt on gas exchange during breath-hold diving: the Scholander and Kooyman legacy. Respir Physiol Neurobiol. 2009;165(1):28-39. Farrell M. K., Drake G. J., Rucker D., Finkelstein M., Zier J. L. Creation of a registered nurse-administered nitrous oxide sedation program for radiology and beyond. Pediatr Nurs. 2008;34(1):29-35; quiz 35-26. Gilchrist L.S., Tanner, L., Hooke, M.C. Measuring chemotherapyinduced peripheral neuropathy in children: Development of the Ped-mTNS and pilot study results. Rehabilitation Oncology. 2009;27(3). Gilchrist L. S., Galantino M. L., Wampler M., Marchese V. G., Morris G. S., Ness K. K. A framework for assessment in oncology rehabilitation. Phys Ther. 2009;89(3):286-306.

Hamming K. K., Finkelstein M., Sidman J. D. Hoarseness in children with cleft palate. Otolaryngol Head Neck Surg. 2009;140(6):902-906.

Kadan-Lottick N. S., Brouwers P., Breiger D., Kaleita T., Dziura J., Northrup V., Chen L., Nicoletti M., Bostrom B., Stork L., Neglia J. P. Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 2009;27(35):5986-5992.

Hamming K. K., Lund T. W., Lander T. A., Sidman J. D. Complications and satisfaction with pediatric osseointegrated external ear prostheses. Laryngoscope. 2009;119(7):1270-1273.

Kang L., Marty D., Pauli R. M., Mendelsohn N. J., Prachand V., Waggoner D. Chondrodysplasia punctata associated with malabsorption from bariatric procedures. Surg Obes Relat Dis. 2009.

Hauck M. R. Expediting care for children: advanced practice nurses as short stay hospitalists. Nurs Adm Q. 2009;33(1):67-69. Hechler T., Blankenburg M., Friedrichsdorf S. J., Garske D., Hubner B., Menke A., Wamsler C., Wolfe J., Zernikow B. Parents’ perspective on symptoms, quality of life, characteristics of death and end-of-life decisions for children dying from cancer. Klin Padiatr. 2008;220(3):166-174.

Karpas A., Finkelstein M., Reid S. Parental preference for rehydration method for children in the emergency department. Pediatr Emerg Care. 2009;25(5):301-306.

Gupta A., Kessler P., Rawwas J., Williams B. R. Regulation of CRABP-II expression by MycN in Wilms tumor. Exp Cell Res. 2008;314(20):3663-3668.

Heman-Ackah S. E., Sidman J., Liu M. Conscious sedation in pediatric speech endoscopy. Int J Pediatr Otorhinolaryngol. 2009;73(12):1686-1690. Herrera L., Bostrom B., Gore L., Sandler E., Lew G., Schlegel P. G., Aquino V., Ghetie V., Vitetta E. S., Schindler J. A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2009;31(12):936941. Hill D. A., Ivanovich J., Priest J. R., Gurnett C. A., Dehner L. P., Desruisseau D., Jarzembowski J. A., Wikenheiser-Brokamp K. A., Suarez B. K., Whelan A. J., Williams G., Bracamontes D., Messinger Y., Goodfellow P. J. DICER1 mutations in familial pleuropulmonary blastoma. Science. 2009;325(5943):965. Hockenberry M. J., Hooke M. C., Gregurich M., McCarthy K. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. J Pediatr Hematol Oncol. 2009;31(9):664-669. Hoff D. S., Michaelson, A. S. Effects of light exposure on total parenteral nutrition and its implications in the neonatal population. J Pediatr Pharmacol Ther. 2009;14:132-143. Hoff D. S., Wilcox R. A., Tollefson L. M., Lipnik P. G., Commers A. R., Liu M. Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates. Pharmacotherapy. 2009;29(11):1297-1305. Hill D. A., Jarzembowski J. A., Priest J. R., Williams G., Schoettler P., Dehner L. P. Type I pleuropulmonary blastoma: pathology and biology study of 51 cases from the international pleuropulmonary blastoma registry. Am J Surg Pathol. 2008;32(2):282-295. Hollenbeck L. Advocating for universal newborn hearing screening. Creat Nurs. 2008;14(2):75-81. Kadan-Lottick N. S., Brouwers P., Breiger D., Kaleita T., Dziura J., Liu H., Chen L., Nicoletti M., Stork L., Bostrom B., Neglia J. P. A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood. 2009;114(9):17461752.

Kaveri S., Gringeri A., Heisel-Kurth M., Kreuz W. Inhibitors in haemophilia A: the role of VWF/FVIII concentrates--a meeting report. Haemophilia. 2009;15(2):587-591. Kerns R.D., Berry S., Frantsve L. E., Linton John C. Life-long competency development in clinical health psychology. Training and Education in Professional Psychology. 2009;3(4):212-217. Kiragu A. W., Zier J., Cornfield D. N. Utility of blood cultures in postoperative pediatric intensive care unit patients. Pediatr Crit Care Med. 2009;10(3):364-368. Ko R. H., Ji L., Barnette P., Bostrom B., Hutchinson R., Raetz E., Seibel N. L., Twist C. J., Eckroth E., Sposto R., Gaynon P. S., Loh M. L. Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study. J Clin Oncol. 2009. Krishnan R.K.M.; Meyers, P.A.; Worwa, C.; Goertz, R.; Schauer, G.; Mammel, M. C. Inadequate Lung Volume Recruitment After Sustained Lung Inflation in High Frequency Oscillatory Ventilation: Pathophysiology and Inflammation in an Animal RDS Model. J Neonatal-Perinatal Med 2008. 2008;1: 93-104. Kurth M. H., Dimichele D., Sexauer C., Sanders J. M., Torres M., Zappa S. C., Ragni M., Leonard N. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia. 2008;14(1):50-55. Lacey C. M., Finkelstein M., Thygeson M. V. The impact of positioning on fear during immunizations: supine versus sitting up. J Pediatr Nurs. 2008;23(3):195-200. Lampland A. L., Meyers P. A., Worwa C. T., Swanson E. C., Mammel M. C. Gas exchange and lung inflammation using nasal intermittent positive-pressure ventilation versus synchronized intermittent mandatory ventilation in piglets with saline lavageinduced lung injury: an observational study. Crit Care Med. 2008;36(1):183-187. Lampland A. L., Plumm B., Meyers P. A., Worwa C. T., Mammel M. C. Observational study of humidified high-flow nasal cannula compared with nasal continuous positive airway pressure. J Pediatr. 2009;154(2):177-182. Lee A., Hankin B. L. Insecure attachment, dysfunctional attitudes, and low self-esteem predicting prospective symptoms of depression and anxiety during adolescence. J Clin Child Adolesc Psychol. 2009;38(2):219-231.


Lidsky M. E., Lander T. A., Sidman J. D. Resolving feeding difficulties with early airway intervention in Pierre Robin Sequence. Laryngoscope. 2008;118(1):120-123. Lin A. E., Basson C. T., Goldmuntz E., Magoulas P. L., McDermott D. A., McDonald-McGinn D. M., McPherson E., Morris C. A., Noonan J., Nowak C., Pierpont M. E., Pyeritz R. E., Rope A. F., Zackai E., Pober B. R. Adults with genetic syndromes and cardiovascular abnormalities: clinical history and management. Genet Med. 2008;10(7):469-494. Macaya D., Katsanis S. H., Hefferon T. W., Audlin S., Mendelsohn N. J., Roggenbuck J., Cutting G. R. A synonymous mutation in TCOF1 causes Treacher Collins syndrome due to mis-splicing of a constitutive exon. Am J Med Genet A. 2009;149A(8):1624-1627. Malone G., Akre M., Hauck M. On the scene at Children’s Hospitals and Clinics of Minnesota. Nurs Adm Q. 2009;33(1):54-61. Mammel M. C. Corticosteroids and hypotension: altered response states and human disease. J Perinatol. 2008;28(12):789-790. Maron B. J., Roberts W. C., Arad M., Haas T. S., Spirito P., Wright G. B., Almquist A. K., Baffa J. M., Saul J. P., Ho C. Y., Seidman J., Seidman C. E. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA. 2009;301(12):1253-1259. Matthews A. L., O’Conner-Von S. Administration of comfort medication at end of life in neonates: effects of weight. Neonatal Netw. 2008;27(4):223-227. McAlinden A., Majava M., Bishop P. N., Perveen R., Black G. C., Pierpont M. E., Ala-Kokko L., Mannikko M. Missense and nonsense mutations in the alternatively-spliced exon 2 of COL2A1 cause the ocular variant of Stickler syndrome. Hum Mutat. 2008;29(1):83-90. Mendelsohn N. J., Schaefer G. B. Genetic evaluation of autism. Semin Pediatr Neurol. 2008;15(1):27-31. Mendelsohn N. J., Messinger Y. H., Rosenberg A. S., Kishnani P. S. Elimination of antibodies to recombinant enzyme in Pompe’s disease. N Engl J Med. 2009;360(2):194-195. Mertens A. C., Sencer S., Myers C. D., Recklitis C., Kadan-Lottick N., Whitton J., Marina N., Robison L. L., Zeltzer L. Complementary and alternative therapy use in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2008;50(1):90-97. Menon S., Pierpont M. E., Driscoll D. Giant cell aortitis and Noonan syndrome. Congenit Heart Dis. 2008;3(4):291-294. Meyer A. C., Kimbrough T. G., Finkelstein M., Sidman J. D. Symptom duration and CT findings in pediatric deep neck infection. Otolaryngol Head Neck Surg. 2009;140(2):183-186. Meyer A. C., Lidsky M. E., Sampson D. E., Lander T. A., Liu M., Sidman J. D. Airway interventions in children with Pierre Robin Sequence. Otolaryngol Head Neck Surg. 2008;138(6):782-787. Moore B. M., Fernbach K. L., Finkelstein M. J., Carolan P. L. Impact of Changes in Infant Death Classification on the Diagnosis of Sudden Infant Death Syndrome. Clin Pediatr (Phila). 2008. Mulrooney D. A., Yeazel M. W., Kawashima T., Mertens A. C., Mitby P., Stovall M., Donaldson S. S., Green D. M., Sklar C. A., Robison L. L., Leisenring W. M. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606. Nathan B. M., Sockalosky J., Nelson L., Lai S., Sergi C., Petryk A. The use of hormonal therapy in pediatric heart disease. Front Biosci (Schol Ed). 2009;1:358-375.


Overman D. M. Invited commentary. Ann Thorac Surg. 2009;87(5):1494. Ozkaynak M. F., Sahdev I., Gross T. G., Levine J. E., Cheerva A. C., Richards M. K., Rozans M. K., Shaw P. J., Kadota R. P. A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study. J Pediatr Hematol Oncol. 2008;30(3):204-209. Pacheco M. C., Campbell K. M., Bove K. E. Ductal plate malformation-like arrays in early explants after a Kasai procedure are independent of splenic malformation complex (heterotaxy). Pediatr Dev Pathol. 2009;12(5):355-360. Payne N. R., Mijal R. S. Re: “Maternal asthma medication use and the risk of gastroschisis”. Am J Epidemiol. 2009;170(2):266; author reply 266-267. Payne N. R., Pfleghaar K., Assel B., Johnson A., Rich R. H. Predicting the outcome of newborns with gastroschisis. J Pediatr Surg. 2009;44(5):918-923. Pearl P. L., Vezina L. G., Saneto R. P., McCarter R., Molloy-Wells E., Heffron A., Trzcinski S., McClintock W. M., Conry J. A., Elling N. J., Goodkin H. P., de Menezes M. S., Ferri R., Gilles E., Kadom N., Gaillard W. D. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia. 2009;50(2):184-194. Perko R., Messinger Y., Moertel C. Pseudometastasis secondary to histoplasmosis infection: False-positive PET/CT findings. Pediatr Blood Cancer. 2009. Pickering L. K., Baker C. J., Freed G. L., Gall S. A., Grogg S. E., Poland G. A., Rodewald L. E., Schaffner W., Stinchfield P., Tan L., Zimmerman R. K., Orenstein W. A. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(6):817-840. Pierpont E. I., Pierpont M. E., Mendelsohn N. J., Roberts A. E., Tworog-Dube E., Seidenberg M. S. Genotype differences in cognitive functioning in Noonan syndrome. Genes Brain Behav. 2008. Post-White J., Fitzgerald M., Hageness S., Sencer S. Complementary and Alternative Medicine Use in Children With Cancer and General and Specialty Pediatrics. J Pediatr Oncol Nurs. 2008. Post-White J., Fitzgerald M., Savik K., Hooke M. C., Hannahan A. B., Sencer S. F. Massage Therapy for Children With Cancer. J Pediatr Oncol Nurs. 2008. Post-White J., Fitzgerald M., Hageness S., Sencer S. F. Complementary and alternative medicine use in children with cancer and general and specialty pediatrics. J Pediatr Oncol Nurs. 2009;26(1):7-15. Post-White J., Fitzgerald M., Savik K., Hooke M. C., Hannahan A. B., Sencer S. F. Massage therapy for children with cancer. J Pediatr Oncol Nurs. 2009;26(1):16-28. Priest J. R., Jaffe A. Reply. Pediatr Pulmonol. 2009. Priest J. R., Williams G. M., Hill D. A., Dehner L. P., Jaffe A. Pulmonary cysts in early childhood and the risk of malignancy. Pediatr Pulmonol. 2009;44(1):14-30. Ramanuja S., Kelkar P. Habit cough. Ann Allergy Asthma Immunol. 2009;102(2):91-95; quiz 95-97, 115.

Rao S. O., Boramanand N. K., Burton D. A., Perry J. C. Atrial tachycardias in young adults and adolescents with congenital heart disease: Conversion using single dose oral sotalol. Int J Cardiol. 2008. Reid S. R., Losek J. D. Rehydration: role for early use of intravenous dextrose. Pediatr Emerg Care. 2009;25(1):49-52; quiz 53-44. Roby B. B., McNamara J., Finkelstein M., Sidman J. Sinus surgery in Cystic Fibrosis patients: Comparison of sinus and lower airway cultures. Int J Pediatr Otorhinolaryngol. 2008;72(9):1365-1369. Rosen G. M. Sleep and wakefulness in children with brain tumors. Sleep Medicine Clinics. 2008;3:455-467. Rosen G. M., Shor A. C., Geller T. J. Sleep in children with cancer. Curr Opin Pediatr. 2008;20(6):676-681. Rother K. I., Brown R. J., Morales M. M., Wright E., Duan Z., Campbell C., Hardin D. S., Popovic J., McEvoy R. C., Harlan D. M., Orlander P. R., Brod S. A. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes. Diabetes Care. 2009;32(7):1250-1255. Saewyc E. M., Solsvig W., Edinburgh L. The Hmong Youth Task Force: evaluation of a coalition to address the sexual exploitation of young runaways. Public Health Nurs. 2008;25(1):69-76. Schaefer G. B., Mendelsohn N. J. Genetics evaluation for the etiologic diagnosis of autism spectrum disorders. Genet Med. 2008;10(1):4-12. Schaefer G. B., Mendelsohn N. J. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders. Genet Med. 2008;10(4):301-305. Schaefer G. B., Mendelsohn N. J. Response to letter by Chodirker and Chudley. Genet Med. 2008;10(11):845. Schiavetti A., Indolfi P., Hill D. A., Priest J. R. Primary pulmonary rhabdomyosarcoma in childhood: clinico-biologic features in two cases with review of the literature--erratum. Pediatr Blood Cancer. 2009;52(1):146. Shutske K., Baker, D., Zustiak, T. Teachable moments: Asthma education in the ED. American Nurse Today. 2009;4(8).

Thygeson M. V. An evidence-based eye: interpreting and evaluating scientific literature. Creat Nurs. 2008;14(1):14-16. Tibesar R. J., Sidman J. D. Mandibular distraction osteogenesis in the pediatric patient. Curr Opin Otolaryngol Head Neck Surg. 2008;16(6):548-554. Volkman H. E., Pozos T. C., Zheng J., Davis J. M., Rawls J. F., Ramakrishnan L. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science. 2009. Whelan K. F., Stratton K., Kawashima T., Waterbor J. W., Castleberry R. P., Stovall M., Sklar C. A., Packer R. J., Mitby P., Aitken C. L., Blatt J., Robison L. L., Mertens A. C. Ocular late effects in childhood and adolescent cancer survivors: a report from the childhood cancer survivor study. Pediatr Blood Cancer.54(1):103-109. Wheless J. W., Carmant L., Bebin M., Conry J. A., Chiron C., Elterman R. D., Frost M., Paolicchi J. M., Donald Shields W., Thiele E. A., Zupanc M. L., Collins S. D. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia. 2009;50(2):195-205. Wilder R. T., Flick R. P., Sprung J., Katusic S. K., Barbaresi W. J., Mickelson C., Gleich S. J., Schroeder D. R., Weaver A. L., Warner D. O. Early exposure to anesthesia and learning disabilities in a population-based birth cohort. Anesthesiology. 2009;110(4):796-804. Zarate Y. A., Pacheco M. C., Bove K. E., Gorlin R., Zhao H., Hopkin R. J. Phenotypic and microscopic description of a new case of Ermine phenotype. Am J Med Genet A. 2009;149A(6):1253-1256. Zenali M. J., Zhang P. L., Bendel A. E., Brown R. E. Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in Ewing family of tumors. Ann Clin Lab Sci. 2009;39(2):160166. Zier J. L., Rivard P. F., Krach L. E., Wendorf H. R. Effectiveness of sedation using nitrous oxide compared with enteral midazolam for botulinum toxin A injections in children. Dev Med Child Neurol. 2008;50(11):854-858.

Sidman J. D., Lander T. A., Finkelstein M. Platelet-rich plasma for pediatric tonsillectomy patients. Laryngoscope. 2008;118(10):17651767. Smith A. R., Hennessy J. M., Kurth M. A., Nelson S. C. Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome. Pediatr Blood Cancer. 2008;51(3):418-420. Smith A. R., Leonard N., Kurth M. H. Intracranial hemorrhage in newborns with hemophilia: the role of screening radiologic studies in the first 7 days of life. J Pediatr Hematol Oncol. 2008;30(1):81-84. Smith E. P., Specker B., Bachrach B. E., Kimbro K. S., Li X. J., Young M. F., Fedarko N. S., Abuzzahab M. J., Frank G. R., Cohen R. M., Lubahn D. B., Korach K. S. Impact on bone of an estrogen receptoralpha gene loss of function mutation. J Clin Endocrinol Metab. 2008. Stinchfield P. K. Practice-proven interventions to increase vaccination rates and broaden the immunization season. Am J Med. 2008;121(7 Suppl 2):S11-21. Symons F. J., Shinde S. K., Gilles E. Perspectives on pain and intellectual disability. J Intellect Disabil Res. 2008;52(Pt 4):275-286.


Research Staff

Row 3 (back row), from L to R: Chris Sigstad; Mary Lamers Tkach; Nicole Hart; Lezlie Rabine; Erin E. Olson; Cathy Worwa; Pat Meyers. Row 2, from L to R: Robert Koepp; Anne Harris; Brenda Plumm; Andrea Nugent; Marsha Finkelstein; Pauline Mitby; Gretchen Williams; Erica Swift; Heidi Vander Velden. Row 1, from L to R: Megan V. Thygeson; Laurie Blumberg-Romero; Houa Vue; Meixia Liu; Kristi Jarvis; Mahrya Johnson. 22

RESEARCH VISION: Children’s Research and Sponsored Programs strives to improve the quality of life for all children and families through innovation and investigation of care, therapies, and technology. We foster transformative research through collaborations within our institution, statewide, and nationally. We create vibrant opportunities by inspiring and motivating Children’s investigators to explore new frontiers.


Research Staff Research and Sponsored Programs Laurie Blumberg-Romero Director Marsha Finkelstein Health Services Research Specialist Meixia Liu Health Services Research Specialist Erica Swift Grants Analyst Megan V. Thygeson Scientific and Technical Writer Cardiovascular and Critical Care/Genetics Kristi Jarvis Clinical Research Coordinator Cardiovascular and Critical Care Research Center Camille Clare Research Assistant Emma Halbrooks Research Assistant Erin E. Olson Clinical Research Associate Cystic Fibrosis Research Mahrya Johnson Sr. Clinical Research Coordinator 24

Lisa Read Clinical Research Associate

Stacy Doering Clinical Research Associate

Diabetes and Endocrinology Research

Courtney Haller Clinical Research Associate

Catherine Girard Clinical Research Coordinator Houa Vue Sr. Clinical Research Coordinator Emergency Department Research Karuna Thomas Research Assistant Grant Accounting Joy Berens Associate Grant Accountant Melissa Ketter Grant Accountant Natalie Ruiz Sr. Grant Accountant Linda Ward Grant Accounting Manager

Anne Harris Clinical Research Associate Nicole Hart Clinical Research Coordinator Jennifer Lee Clinical Research Associate Robert Koepp IRB & Research Support Coordinator Ann Logelin Clinical Research Associate Pauline Mitby Sr. Clinical Research Coordinator Lezlie Rabine Clinical Research Associate

Infant Diagnostic and Research Center Molly Maxwell Clinical Research Coordinator Pat Meyers Sr. Clinical Research Coordinator Brenda Plumm Research Associate Cathy Worwa Clinical Research Coordinator Institutional Review Board Don Brunnquell Chair Elizabeth Campbell IRB Administrator Integrative Medicine Research Heidi Vander Velden Clinical Research Coordinator Laboratory

Hematology/Oncology Research

Chris Sigstad Clinical Research Associate

Lisa Kappenman Laboratory Research Specialist

Amy Babcock Clinical Research Associate

Mary Lamers Tkach Clinical Research Associate

Pain and Palliative Care Research

Ann Blake Administrative Assistant

Gretchen Williams Clinical Research Coordinator

Andrea Nugent Clinical Research Coordinator


Published by Children’s Hospitals and Clinics of Minnesota Laurie Blumberg-Romero Director, research and sponsored programs Megan V. Thygeson Scientific and technical writer Erica Swift Grants analyst Bruce Bostrom, MD Physician sponsor Trudy Marshall Manager, internal and cornerstone communications Tera Bollig Communications specialist Stanley Wai Graphic designer Brady Willette Photographer Michael Haug Photographer Rick Peterson Illustrator

Mail Stop 50-216S 2525 Chicago Avenue South Minneapolis, MN 55404


Annual Research Report  
Annual Research Report  

Annual Research Report